TY - JOUR T1 - Hepatotoxicity Associated With Vismodegib JF - BMJ Case Reports DO - 10.1136/bcr-2017-222969 VL - 2018 SP - bcr-2017-222969 AU - Prabhjot S Bedi AU - Manoj P Rai AU - Nishant Tageja AU - Heather Laird-Fick Y1 - 2018/02/08 UR - http://casereports.bmj.com/content/2018/bcr-2017-222969.abstract N2 - An 82-year-old Caucasian woman with a history of basal cell carcinoma on vismodegib presented with nausea, vomiting and intermittent abdominal pain. Laboratory results were remarkable for the elevation of liver enzymes. Endoscopic retrograde cholangiopancreatography and percutaneous transhepatic cholangiogram (PTC) did not show evidence of intrahepatic or extrahepatic obstruction of the biliary tract. During PTC external biliary catheter was placed; however, bilirubin continued to rise. Further, laboratory work-up and imaging studies ruled out other possible aetiologies for hepatotoxicity such as infections, autoimmune hepatitis and other drugs known to be hepatotoxic thus leaving vismodegib the most likely cause of hepatotoxicity. ER -